News | February 18, 2008

Report Finds Med Tech Price Disclosure Would Likely Increase Prices

February 19, 2008 - A new study released today found pending congressional legislation seeking the mandatory disclosure of prices for certain medical technologies might result in increased prices and no tangible benefits to patients.

The study, released today at the National Press Club by its authors Robert W. Hahn, executive director, Reg-Markets Center and senior fellow at the American Enterprise Institute, and Hal J. Singer, president of Criterion Economics, examines the potential economic impact of the Transparency in Medical Device Pricing Act of 2007 (S. 2221), recently introduced in the U.S. Senate.

In the report, the researchers review previous attempts by governments to impose price disclosure rules in a number of other industries including cell phones, groceries, cement, barges, railroads and long-distance telephone services. The authors use evidence from case studies and other sources to identify four conditions that, if satisfied, imply that mandatory price disclosure would provide large benefits to consumers or other purchasers.

“We found that mandatory price disclosure, as proposed in S.2221 is unlikely to benefit patients or hospitals and worse, will likely increase costs,” Hahn said.

The authors write that in order for price disclosure to have a favorable effect, there must be large search costs that are reduced substantially, and that the pricing information disclosed be current. The industry-specific market conditions essential for lower prices to occur would require that any savings be passed on to end users, and that there is a large variation in the price paid by purchasers and consumers.

Specifically, the report found the medical device industry is concentrated among a few firms and competitors repeatedly interact in the marketplace. There are few, if any, economical substitutes for many medical devices. Some medical devices are standardized, whereas other devices are differentiated. The report also found that most of the firms do not already know their rivals’ prices.

The report conclude that significant search costs for hospitals and patients would remain and disclosure would not provide current price information, since the data would be at least three months old. The report also concluded the structure of the healthcare industry would not ensure that hospitals pass cost savings on to consumers.

“Applying these conditions to the medical device industry, we conclude that mandatory price disclosure policy would likely increase prices hospitals pay for these products and provide no tangible benefit to patients,” the authors said.

The study was supported by the Advanced Medical Technology Association.

For more information: www.criterioneconomics.com

Related Content

Siemens Healthineers Announces First U.S. Install of Artis Pheno Angiography System
News | Angiography| July 05, 2017
Michigan Medicine recently became the first healthcare institution in the United States to install the Artis pheno, the...
Sponsored Content | Videos | Angiography| June 22, 2017
Shimadzu Medical Systems highlighted new features of its Trinias Interventional X-ray line at the America College of
Sponsored Content | Videos | Angiography| May 03, 2017
Tom Kloetzly, sales and marketing VP for Shimadzu Medical Systems USA, explains the evolution of Shimadzu Corporation...
New Hampshire Hospital Expands Vascular Care with Toshiba Medical's Infinix-I Sky +
News | Angiography| April 27, 2017
Wentworth-Douglass Hospital in Dover, N.H., installed Toshiba Medical’s Infinix-i Sky + angiography system in its...
Louisiana Medical Center Installs First U.S. Toshiba Medical Infinix-i Sky +
News | Angiography| April 18, 2017
April 18, 2017 — Patients at Terrebonne General Medical Center (TGMC) in Houma, La., now have access to safe, high-qu
Sponsored Content | Videos | ACC| April 03, 2017
DAIC Editor Dave Fornell takes a tour of some of the interesting new technologies from the vendor booths on the expo
tryton side branch stent, dedicated coronary side branch stent

The FDA approval of the Tryton Side Branch Stent was the biggest technology news from March. It is deployed in the side branch artery using a standard single wire balloon-expandable stent delivery system. A conventional drug eluting stent is then placed in the main vessel.

Feature | April 03, 2017 | Dave Fornell
April 3, 2017 — Here is the list of the top 25 most popular pieces of content on the Diagnostic and Interventional Ca
Sponsored Content | Videos | Cath Lab| March 28, 2017
MDBuyline analyst Tom Watson shares some of the most important trends in cardiac technology he saw at the 2017 Americ
Philips, cardiology solutions, ACC.17, Azurion angiography system, iFR outcomes results, IntelliSpace Cardiovascular
News | Cardiac Imaging| March 24, 2017
At the 2017 American College of Cardiology's Annual Scientific Session & Expo (ACC.17), Philips showcased a broad...
Siemens Healthineers, ACC 2017, syngot CTO Guidance, Compressed Sensing Cardiac Cine
News | Cardiac Imaging| March 16, 2017
During the 66th Annual Scientific Session & Expo of the American College of Cardiology (ACC), March 17-19 in...
Overlay Init